HOWARU-HN001-Cropped

HOWARU® HN001™

HOWARU® HN001™

Lacticaseibacillus rhamnosus HN001™

Image credits: © IFF, Finland, 2021 (FESEM imaging VTT)

HOWARU® Lacticaseibacillus rhamnosus HN001™ has been consumed for more than 20 years in foods and supplements and documented in more than 200 scientific publications. It was originally selected as a probiotic candidate due to its high tolerance to acidic conditions and was subsequently shown to survive passage through the human intestine.¹⁻³​

Product Information:

~ 99 preclinical trial publications
~ 85+ clinical trial publications

Health Benefits:
Women’s HealthWomen's

Bi-07® BLENDS

Learn more about IFF Health Sciences’ Bi-07® blends.

IFF_HS_Our-Products_HOWARU-Feminine-Health_1_Edit_final

HOWARU® Feminine Health

Howaru-Protect-Early-Life_Cropped

HOWARU® Protect Early Life

IFF_HS_Our-Products_HOWARU-Prenatal-Plus_2_cropped

HOWARU® Protect Prenatal +

HN001™ CLINICAL STUDIES & PUBLICATIONS​

HN001™ has been extensively studied across all life stages—from early infancy through elderly years and in pregnant and lactating women.

Most notable is its ability to impact the immune system and long-term safety profile in infants and children to support early life immune homeostasis.³⁻⁶

Also, when combined with La-14®, HN001™ supports healthy vaginal colonization and microbiota for women’s intimate health as HOWARU® Feminine Health

DSC09478

Health Benefit Areas

Each strain’s health benefits are supported by recommended daily doses and peer-reviewed clinical studies.

Click on a Health Benefit to see more studies and learn more.

References: 1. Prasad J et al.; Int Dairy J. 1998; 2. Tannock GW et al.;Appl Environ Microbiol. 2000; 3. Wickens K et al.;J Allergy Clin Immunol. 2008; 4. Wickens K et al.;Clin Exp Allergy. 2012; 5. Wickens K et al.; Clin Exp Allergy. 2013; 6. Wickens K et al.;Pediatr Allergy Immunol. 2018; 7. De Alberti D et al.;Arch Gynecol Obstet. 2015.​